SACI-IO HR+: A Randomized Phase II Trial of Sacituzumab Govitecan with or Without Pembrolizumab in Patients with Metastatic Hormone Receptor-Positive/her2-negative Breast Cancer.

Ana Christina Garrido-Castro,Se Eun Kim, Jennifer Desrosiers,Rita Nanda,Lisa A. Carey,Amy Sanders Clark,Ruth Lauren Sacks, Thomas Patrick O'Connor,Natalie Faye Sinclair,K. M. Steve Lo, Amy Thomas,Eileen Wrabel,Tess O'Meara,Nancy U. Lin,Harold J. Burstein, Mengni He,David L. Rimm,Elizabeth A. Mittendorf,Nabihah Tayob,Sara M. Tolaney

JOURNAL OF CLINICAL ONCOLOGY（2024）

引用 0|浏览4

暂无评分

关键词

283-217-7597,261-492-3532-2370-7650-2700,261-492-3532-2373,261-492-199,261-566-3248-9542-7750,3282-206-3220-6287,3282-3306-4614-3760,242,1876,242,1614,1876,16,38092-33344,38092-20072,38092-34807,38092-29187,38092-24902,38092-22447,38092-20232,38092-20225

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要